IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...
Investing.com - TD Cowen lowered its price target on Beta Bionics, Inc. (NASDAQ:BBNX) to $16.00 from $17.00 while maintaining a Hold rating on the shares. This target sits within the broader analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results